Receive The Newest Study Notifications

Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of...

- First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy - New cohort added under existing collaborative...

Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients Recently initiated Phase 2 portion of ProSTAR includes randomized testing of CPI-1205 in combination with enzalutamide versus enzalutamide...

Median overall survival was 21.9 months for highest vaccine dose vs. 14.6 months in published standard of care studies Median progression-free survival was 10.4 months vs. 6.9 and 5.4 months in published standard of care studies Results presented today at the American...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated...

No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted...

George Clinical, a global scientifically backed clinical research organization, (CRO) has expanded its footprint in Asia with the addition of a new presence in Singapore. The new office and entity in Singapore, which was established in July, were requisites for George...

Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim...

- Design of cervical cancer study amended in anticipation for regulatory interactions -             -  Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung cancer; IOV-LUN-201 study to close - Iovance Biotherapeutics, Inc. (NASDAQ:...

Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States. QUE...

Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint PSA trajectory in patient achieving primary efficacy endpoint indicates alteration of the natural history of...

Epic Sciences, Inc. and its research partners today report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant...

This webinar will discuss the importance of thorough, accurate and timely reporting of adverse events from feasibility studies through post-market clinical trials, as well as how medical device development teams can follow best practices in using the information in...

The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented at the AACR Annual...

Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of...

Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today summarized its efforts to...

Modern medicines have positively contributed to public health and changed the ways human diseases are prevented and treated. Yet, most drugs are not without side effects. Adverse drug reactions (ADRs) rank among the leading causes of morbidity and mortality worldwide....

Stand Up To Cancer (SU2C) is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors such as osteosarcoma and...

- 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit...

The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were...